Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023 - KPLC 7 News, Lake Charles, Louisiana

Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, Jan. 21, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023

Report Details

Myeloma medicines - now discover R&D trends, opportunities, and potential revenues
What are the commercial prospects for treating multiple myeloma? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, technological developments, opportunities, and commercial outlooks.

In that new analysis you discover sales forecasts to 2023 at overall world market, submarket, product, and national level for those drugs. You also assess technologies, competition, and progress for treating that cancer. There find data and potentials.
Read on to explore those products and see what their future market could be worth.

Forecasts to 2023 and other information to benefit your research and analysis

Besides revenue predictions to 2023, our report gives you recent results, growth rates, and market shares. There you discover original analysis, seeing outlooks for business and developments (R&D). You also get 64 tables, 57 charts, and two interviews.

Assessment of that medical industry, showing data you need

In that study you hear what's happening for those anti-cancer medicines, learning where needs and money lie. Now see how you and your organisation can gain.

Avoid falling behind or losing influence. Instead discover information you need to stay ahead. Our study assesses those pharmaceuticals for blood cancers (haematological malignancies), helping you save time and benefit your research, analyses, and decisions.

The following sections show, then, what you get in that new investigation.

Forecasting of the world market and segments for that cancer therapy

Discover in our report overall world drug revenue to 2023 for multiple myeloma. You also see individual revenue predictions for five therapeutic submarkets at world level:
• Immunomodulators
• Proteasome inhibitors
• Monoclonal antibodies (mAbs)
• Kinase inhibitors
• Other agents.

How will sales of those therapies expand? Which drug classes will generate most money? There you assess prospects for revenue growth, seeing where you can benefit from the treatment of multiple myeloma (plasma cell myeloma or Kahler's disease).

You also discover forecasts by agent, seeing how they can succeed.

Predictions for myeloma-treating products - find what revenues are possible

How will those cancer-treating drugs perform to 2023 at world level? Our study forecasts myeloma sales of six top brands and four expected medicines, including these:
• Revlimid
• Velcade
• Thalomid
• Zometa
• Pomalyst
• Elotuzumab.

There you find each agent's potential. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

You also find geographical predictions.

National markets - where will highest revenues and sales growth occur?

In developed and developing countries, multiple myeloma therapies will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potentials.

In our report you find individual revenue forecasts to 2023 for 11 national markets:
United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.

There you find countries with highest revenues and predicted sales growth. Our work explains. Discover the future of those products, hearing about progress in that healthcare field and seeing what it means.

There you assess trends in oncology and tackling those diseases.

Issues affecting developers, producers, and sellers of myeloma-treating medicines

Our study explains forces affecting that industry and market from 2013, including these:
• Therapy by induction, maintenance, and salvage methods
• Research and development (R&D) for those blood and bone marrow disorders
• Governmental support for developing and marketing therapies
• Prospects and capabilities of companies investigating that oncology.

There you assess developments, finding advances and outlooks for business. Discover what the present and future hold.

Companies and overall 2017 market value - how high can its revenues go?

From 2013, myeloma treatments hold potential for investments, medical advances, and higher revenues. Our analysis predicts that overall world market will reach $11.5bn in 2017, expanding to 2023.

That work shows you what technologies and organisations hold greatest potential. In particular, you explore these companies:
• Celgene
• Johnson & Johnson (J&J)
• Takeda
• Novartis
• Bristol-Myers Squibb
• Onyx Pharmaceuticals.

See what's possible for that industry. Our investigation explains the potential of its market, helping you stay ahead.

Information found nowhere else - discover the future of those cancer-treating drugs

Through knowledge such as this, our report helps you get recognition for insight:
• Revenues to 2023 at world level, with forecasting of 5 submarkets, and 10 products - investigate prospects for investments and revenues
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - assess countries for therapeutic needs, business, and expected sales growth
• Prospects for companies - explore portfolios, results, R&D, and outlooks.

Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023 gives independent analysis. There you receive competitive intelligence found only in our work.

That new study helps you find the money and show your authority on that technology. Gain now by trying that report.

Anti-myeloma agents - find commercial potentials by ordering now

Our new report is for everyone investigating cancer of plasma cells (haematological malignancy) and its treatment market. There you discover revenue forecasts to 2023, with discussions of those technologies. Avoid missing out - please order now.

1. Executive Summary

1.1 What This Report Covers
1.2 Multiple Myeloma: World Drug Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to Multiple Myeloma and its Treatment

2.1 What is Multiple Myeloma?
2.2 What Are Plasma Cells?
2.3 What Causes Multiple Myeloma?
2.4 Signs and Symptoms of the Disease
2.5 Demographic Risk Variation in Multiple Myeloma
2.6 Stages of the Disease
2.6.1 The Durie-Salmon Staging System and the International Staging System
2.7 Treatment of Multiple Myeloma
2.7.1 Induction Therapy
2.7.2 Maintenance Therapy
2.7.3 Salvage Therapy
2.8 Present and Future Options for Treating Multiple Myeloma: Summary

3. The World Multiple Myeloma Drug Treatment Market, 2013-2023

3.1 The World Multiple Myeloma Drug Treatment Market in 2012
3.2 Multiple Myeloma Drug Treatment: Overarching Market Forecast 2013-2023
3.3 World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Comparison of Revenue and Market Share, 2018 and 2023
3.4 The World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Grouped Revenue Forecasts, 2013-2023
3.5 Immunomodulators for Multiple Myeloma: Dominating the Market Throughout the Forecast Period
3.5.1 Immunomodulators: Revenue Forecast 2013-2023
3.6 Proteasome Inhibitors: A Cornerstone in Multiple Myeloma Drug Treatment
3.6.1 Proteasome Inhibitors: Revenue Forecast 2013-2023
3.7 Monoclonal Antibodies: Market Launch Anticipated in 2015
3.7.1 Monoclonal Antibodies: Revenue Forecast 2013-2023
3.8 Kinase Inhibitors: A Class of Advanced Cancer Medications
3.8.1 Kinase Inhibitors: Revenue Forecast 2013-2023
3.9 Summary: Growth of the Multiple Myeloma Drug Treatment Market, 2013-2023

4. Leading National Markets for Multiple Myeloma Drug Treatment, 2013-2023

4.1 The Leading National Markets in 2012
4.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 2023
4.3 The Leading National Markets for Multiple Myeloma Drug Treatment: Grouped Revenue Forecasts, 2013-2023
4.4 The US Will Continue to Dominate the Multiple Myeloma Drug Treatment Market from 2013-2023
4.5 The EU5 Countries
4.5.1 Germany: The Largest EU5 Market Will Have the Lowest Levels of Growth
4.5.2 France: Steadily Decreasing Market Share
4.5.3 Italy: High Growth Between 2013 and 2016
4.5.4 The UK: Strongest Growth of the EU5 from 2018-2023
4.5.5 Spain: The Smallest Market of the EU5
4.6 Japan: Delays in Regulatory Approval
4.7 China: Pursuing Domestic Oncology R&D
4.8 Brazil: Governmental Healthcare Investments Support Growth
4.9 Russia: Poor Treatment Outcomes Mean Demand for More-Effective Therapy is High
4.10 India: A Strong Domestic Drug Industry Limits Market Share

5. The Leading Drugs of the World Multiple Myeloma Market, 2013-2023

5.1 Immunomodulators and Proteasome Inhibitors Dominate the Market in 2012
5.2 Leading Multiple Myeloma Drugs: Comparison of Revenue and Market Share, 2018 and 2023
5.3 Leading Multiple Myeloma Drugs: Grouped Revenue Forecasts, 2013-2023
5.4 Revlimid: Market Domination Will Continue
5.4.1 Revlimid: Driving and Restraining Forces
5.4.2 Revlimid: Revenue Forecast 2013-2023
5.5 Velcade: Generic Competition Expected
5.5.1 The Driving and Restraining Factors for Velcade
5.5.2 Velcade: Revenue Forecast 2013-2023
5.6 Thalomid: A 1st Line Treatment, But Revenue is Declining
5.6.1 Driving and Restraining Factors for Thalomid
5.6.2 Thalomid: Revenue Forecast, 2013-2023
5.7 Zometa: Facing Generic Competition
5.7.1 Driving and Restraining Factors for Zometa
5.7.2 Zometa: Revenue Forecast, 2013-2023
5.8 Kyprolis: The 2nd Generation Proteasome Inhibitor Will Capture a Large Market Share
5.8.1 The Driving and Restraining Factors for Kyprolis
5.8.2 Kyprolis: Revenue Forecast, 2013-2023
5.9 Pomalyst: Celgene's 3rd Immunomodulator, But Will it Supersede its Predecessors?
5.9.1 Driving and Restraining Factors for Pomalyst
5.9.2 Pomalyst: Revenue Forecast 2013-2023
5.10 Promising Drugs in the R&D Pipeline
5.10.1 Elotuzumab: The 1st Monoclonal Antibody for MM?
5.10.1.1 Elotuzumab: Driving and Restraining Forces
5.10.1.2 Elotuzumab: Revenue Forecast, 2013-2023
5.10.2 MLN9708: A Game Changing Proteasome Inhibitor?
5.10.2.1 MLN9708: Driving and Restraining Factors
5.10.2.2 MLN9708: Revenue Forecast, 2013-2023
5.10.3 Panobinostat: A First-in-Class Therapy
5.10.3.1 Panobinostat: Driving and Restraining Factors
5.10.3.2 Panobinostat: Revenue Forecast, 2013-2023
5.10.4 Aplidin: A Marine-Derived Compound for the Treatment of Multiple Myeloma
5.10.4.1 Aplidin: Driving and Restraining Factors
5.10.4.2 Aplidin: Revenue Forecast, 2013-2023
5.11 Late-Stage Product Candidates

6. Multiple Myeloma: R&D Pipeline, 2013

6.1 The Small-Molecule Drug Pipeline
6.1.1 Five Candidates in Phase III Development
6.1.1.1 Novartis' Panobinostat
6.1.1.2 AB Science's Masitinib
6.1.1.3 Millennium Pharmaceuticals' MLN9708 (ixazomib)
6.1.1.4 PharmaMar's Aplidin
6.1.1.5 Otsuka America Pharmaceutical's Busulfex
6.1.2 Candidates in Phase II Development: An Abundance of Kinase Inhibitors
6.1.2.1 Oncopeptides' Melflufen
6.1.2.2 Merck's Dinaciclib
6.1.2.3 Astra Zeneca's Selumetinib
6.1.2.4 Pharmacyclics' Ibrutinib
6.1.2.5 Geron Corporation's Imetelstat
6.1.2.6 Celgene's Istodax
6.1.2.7 Bristol-Myers Squibb's Dasatinib
6.1.2.8 Cephalon's Treanda
6.1.2.9 Pfizer's Torisel
6.1.2.10 Novartis' Everolimus
6.1.2.11 Millennium Pharmaceuticals' MLN8237
6.1.2.12 Bayer and Onyx Pharmaceuticals' Nexavar
6.1.3 Candidates in Phase I Development
6.1.3.1 GlaxoSmithKline's GSK2110183 (afuresertib): Development Apparently Suspended
6.1.3.2 Array BioPharma's Arry-520
6.1.3.3 Arno Therapeutics' AR-42
6.1.3.4 EntreMed's ENMD-2076
6.1.3.5 Genentech's Erivedge
6.1.3.6 Allos Therapeutics' Folotyn
6.1.3.7 Synta Pharmaceuticals' Ganetespib
6.2 The Biologic Drug Pipeline: Monoclonal Antibodies Dominate
6.2.1 Three Monoclonal Antibodies Dominate the Phase III Developmental Pipeline
6.2.1.1 Elotuzumab Being Developed Under a Collaboration Between Bristol-Myers Squibb and AbbVie
6.2.1.2 Amgen's Xgeva: Could it Supersede Zometa?
6.2.1.3 Janssen Biotech and Genmab's Daratumumab
6.2.2 Candidates in Phase II Development
6.2.2.1 Novartis' HCD122 (Lucatumumab): Development Appears to Have Stalled
6.2.2.2 Senesco Technologies' SNS01-T
6.2.2.3 Gliknik's GL-0817
6.2.2.4 Celldex Therapeutics' CDX-1401
6.2.2.5 Janssen's Siltuximab
6.2.2.6 Roche's Avastin
6.2.2.7 GlaxoSmithKline's Bexxar
6.2.2.8 Novartis' BHQ880
6.2.2.9 Cell Genesys' GVAX
6.2.2.10 Oncovir's Hiltonol
6.2.3 Candidates in Phase I Development
6.2.3.1 Genentech's DFRF4539A
6.2.3.2 ImmunoGen's Lorvotuzumab Mertansine
6.2.3.3 Eli Lilly's Tabalumab
6.2.3.4 Genentech's MFGR1877S
6.2.3.5 Oncolytics' Reolysin
6.3 Future Epigenetics-Based Treatments

7. The Leading Companies of the Multiple Myeloma Drug Treatment Market, 2013

7.1 The Leading Companies in 2012
7.2 Celgene Corporation is the Market Leader
7.3 Johnson & Johnson: Proteasome and MAb Leader
7.4 Takeda: A Strong Portfolio Through Subsidiary Millennium Pharmaceuticals
7.5 Novartis: A Small Market Share in 2012, But a Well-Stocked Pipeline
7.6 Bristol-Myers Squibb: Poised for Market Entry
7.7 Onyx Pharmaceuticals: Now Part of Amgen

8. Qualitative Analysis of the Multiple Myeloma Drug Treatment Market

8.1 Strengths and Weaknesses of the Multiple Myeloma Drug Treatment Market, 2013
8.1.1 Proven Commercial Viability of the Multiple Myeloma Drug Treatment Market
8.1.2 Use of Combination Therapies Mean the Market Can Sustain a High Number of Products
8.1.3 As a Result, The R&D Pipeline is Well Stocked
8.1.4 Governmental Incentives are Helping to Drive this R&D Effort
8.1.5 But Multiple Myeloma Remains an Incurable Disease
8.1.6 Few Products Dominating that Market: a Weakness?
8.2 Opportunities and Threats Facing the Multiple Myeloma Drug Treatment Market, 2013-2023
8.2.1 Oncology is a Growth Area for Investment, Creating Opportunities in the Market
8.2.2 Will Oncology Remain a Strong Investment for Pharma?
8.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Multiple Myeloma Drug Industry and Market, 2013-2023
8.3.1 Social: Adherence, Support and Education are Crucial
8.3.2 Technological: Increasing Understanding of Cancer Biology
8.3.3 Economic: Stretched Healthcare Budgets Will Affect that Drug Industry
8.3.4 Political: Broadening and Narrowing of Governmental Healthcare Spending

9. Research Interviews from Our Survey

9.1 Interview with Dr Paul Richardson, MD, R.J. Corman Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at the Dana-Farber Cancer Institute
9.1.1 On the Current State of the Multiple Myeloma Drug Market
9.1.2 On the Potential of the Novel Treatments, Pomalidomide and Carfilzomib
9.1.3 On the Future of Multiple Myeloma Treatment
9.2 Interview with an External Authority in the Field (Views Given Anonymously)
9.2.1 Recent Research: Obesity is a Strong Risk Factor for Multiple Myeloma
9.2.2 Multiple Myeloma Treatment: Proactive versus Reactive
9.2.3 Treatment Options for Obese Patients
9.2.4 Multiple Myeloma Incidence Will Increase Owing to Obesity

10. Conclusions from Our Research and Analysis

10.1 The World Multiple Myeloma Drug Treatment Market, 2013-2023
10.2 The Leading National Markets for Multiple Myeloma Drug Treatments, 2013-2023
10.3 The Leading Products in the Multiple Myeloma Drug Treatment Market, 2013-2023
10.4 Trends in the Industry and Market
10.4.1 Multiple Myeloma Treatment is a Thriving Market That Will Continue to Expand
10.4.2 The R&D Pipeline is Large and Diverse
10.4.3 The Small Patient Population Generates Uncertainty

List of Tables

Table 1.1 Currency Exchange Rates,
Table 2.1 Drugs Indicated for the Treatment of Multiple Myeloma: Brand Name, Generic Name and Therapeutic Class, 2013
Table 3.1 The World Multiple Myeloma Drug Market by Therapeutic Class: Revenue ($m) and Market Share (%), 2012
Table 3.2 World Multiple Myeloma Drug Market: Overall Revenue Forecast ($m), 2013-2023
Table 3.3 The Multiple Myeloma Drug Market by Therapeutic Class: Comparison of Revenue ($m) and Market Share (%), 2018 and 2023
Table 3.4 Multiple Myeloma Drug Market by Therapeutic Subclass: Group Revenue ($m) and Market Share (%) Forecasts, 2013-2023
Table 3.5 Immunomodulators for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 3.6 Proteasome Inhibitors for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 3.7 Monoclonal Antibodies for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 3.8 Kinase Inhibitors for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.1 The Leading National Markets: Revenue ($m) and Market Share (%), 2012
Table 4.2 The Leading National Markets: Comparison of Revenue ($m) and Market Share (%), 2018 and 2023
Table 4.3 The Leading National Markets: Grouped Revenue Forecasts ($m), 2013-2023
Table 4.4 The US Multiple Myeloma Drug Treatment Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.5 The EU5 Multiple Myeloma Market by Country: Revenue ($m) and Market Share (%) Forecasts, 2013-2023
Table 4.6 The German Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.7 The French Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.8 The Italian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.9 The UK Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.10 The Spanish Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.11 The Japanese Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.12 The Chinese Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.13 The Brazilian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.14 The Russian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 4.15 The Indian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.1 The Leading Drugs for Multiple Myeloma: Revenue ($m) and Market Share (%), 2012
Table 5.2 Leading Drugs for MM: Comparison of Revenue ($m) and Market Share (%), 2018 and 2023
Table 5.3 Leading MM Drugs: Grouped Revenue Forecasts ($m), 2013-2023
Table 5.4 Revlimid: Key Facts
Table 5.5 Revlimid: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.6 Velcade: Key Facts
Table 5.7 Velcade: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.8 Thalomid: Key Facts
Table 5.9 Thalomid: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.10 Zometa: Key Facts
Table 5.11 Zometa: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.12 Kyprolis: Key Facts
Table 5.13 Kyprolis: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.14 Pomalyst: Key Facts
Table 5.15 Pomalyst: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.16 Elotuzumab: Key Facts
Table 5.17 Elotuzumab: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.18 MLN9708: Key Facts
Table 5.19 MLN9708: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.20 Panobinostat: Key Facts
Table 5.21 Panobinostat: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 5.22 Aplidin: Key Facts
Table 5.23 Aplidin: Revenue ($m) and Market Share (%) Forecast, 2013-2023
Table 6.1 Small Molecule Candidates in Phase III Development for MM, 2013
Table 6.2 Small Molecule Candidates in Phase II Development for MM, 2013
Table 6.3 Small Molecule Candidates in Phase I Development for MM, 2013
Table 6.4 Biologic Candidates in Phase III Development for MM, 2013
Table 6.5 Biologic Candidates in Phase II Development for MM, 2013
Table 6.6 Biologic Candidates in Phase I Development for MM, 2013
Table 7.1 The Leading Companies in the MM Drug Market: Revenue ($m) and Market Share (%), 2012
Table 7.2 Celgene: Multiple Myeloma Product Portfolio, 2013
Table 7.3 Johnson & Johnson: Multiple Myeloma Product Portfolio, 2013
Table 7.4 Takeda: Multiple Myeloma Product Portfolio, 2013
Table 7.5 Novartis: Multiple Myeloma Product Portfolio, 2013
Table 7.6 Bristol-Myers Squibb: Multiple Myeloma Product Portfolio, 2013
Table 7.7 Amgen: Multiple Myeloma Product Portfolio, 2013
Table 8.1 Strengths and Weaknesses of the Multiple Myeloma Drug Treatment Market, 2013
Table 8.2 Opportunities and Threats Facing the Multiple Myeloma Drug Treatment Market, 2013-2023
Table 8.3 The Social, Technological, Economic and Political Factors Influencing the MM Drug Treatment Market, 2013-2023

List of Figures

Figure 2.1 The Incidence Rate of Multiple Myeloma (per 100,000) by World Region, 2008
Figure 3.1 The World Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2012
Figure 3.2 The World Multiple Myeloma Drug Treatment Market: Revenue Forecast ($m), 2013-2023
Figure 3.3 The Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2018
Figure 3.4 The Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2023
Figure 3.5 The Multiple Myeloma Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2013-2023
Figure 3.6 Immunomodulators for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.7 Proteasome Inhibitors for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.8 Monoclonal Antibodies for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.9 Kinase Inhibitors for Multiple Myeloma: Revenue Forecast ($m), 2013-2023
Figure 3.10 The Multiple Myeloma Drug Treatment Market: Driving and Restraining Factors, 2013
Figure 4.1 The Leading National Markets: Market Shares (%), 2012
Figure 4.2 The Leading National Markets for Multiple Myeloma: Market Share (%), 2018
Figure 4.3 The Leading National Markets for Multiple Myeloma: Market Share (%), 2023
Figure 4.4 The US Multiple Myeloma Drug Treatment Market: Revenue Forecast ($m), 2013-2023
Figure 4.5 US: Multiple Myeloma Drug Market Penetration - Usage of Revlimid, Velcade and Thalomid in Early Stage of Disease (%), 2011
Figure 4.6 US: Multiple Myeloma Drug Market Penetration - Usage of Revlimid, Velcade and Thalomid in Late Stages of Disease (%), 2011
Figure 4.7 The EU5 Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.8 The German Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.9 The French Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.10 The Italian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.11 The UK Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.12 The Spanish Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.13 The Japanese Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.14 The Chinese Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.15 The Brazilian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.16 The Russian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 4.17 The Indian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
Figure 5.1 The Leading Drugs for MM: Market Share (%), 2012
Figure 5.2 Leading Drugs for MM: Market Share (%), 2018
Figure 5.3 Leading MM Drugs: Market Share (%), 2023
Figure 5.4 Revlimid: Drivers and Restraints, 2013-2023
Figure 5.5 Revlimid: Revenue Forecast ($m), 2013-2023
Figure 5.6 Velcade: Driving and Restraining Forces, 2013-2023
Figure 5.7 Velcade: Revenue Forecast ($m), 2013-2023
Figure 5.8 Thalomid: Driving and Restraining Forces, 2013-2023
Figure 5.9 Thalomid: Revenue Forecast ($m), 2013-2023
Figure 5.10 Zometa: Driving and Restraining Forces, 2013-2023
Figure 5.11 Zometa: Revenue Forecast ($m), 2013-2023
Figure 5.12 Kyprolis: Driving and Restraining Factors, 2013-2023
Figure 5.13 Kyprolis: Revenue Forecast ($m), 2013-2023
Figure 5.14 Pomalyst: Driving and Restraining Forces, 2013-2023
Figure 5.15 Pomalyst: Revenue Forecast ($m), 2013-2023
Figure 5.16 Elotuzumab: Driving and Restraining Forces, 2013-2023
Figure 5.17 Elotuzumab: Revenue Forecast ($m), 2013-2023
Figure 5.18 MLN9708: Driving and Restraining Factors, 2013-2023
Figure 5.19 MLN9708: Revenue Forecast ($m), 2013-2023
Figure 5.20 Panobinostat: Driving and Restraining Forces, 2013-2023
Figure 5.21 Panobinostat: Revenue Forecast ($m), 2013-2023
Figure 5.22 Aplidin: Driving and Restraining Forces, 2013-2023
Figure 5.23 Aplidin: Revenue Forecast ($m), 2013-2023
Figure 6.1 Breakdown of Small Molecule Drug Pipeline by Development Phase (%), 2013
Figure 6.2 Breakdown of Biologic Drug Pipeline by Development Phase (%), 2013
Figure 7.1 Leading Companies in the MM Drug Market: Market Share (%), 2012
Figure 10.1 The World MM Drug Treatment Market: Breakdown of Revenue ($m) by Therapeutic Class, 2012
Figure 10.2 The MM Drug Treatment Market: Revenue ($m) by Country, 2012, 2018 and 2023
Figure 10.3 Leading Drugs of the Multiple Myeloma Market: Comparison of Revenue ($m), 2012, 2018 and 2023

Companies Listed

AB Science
Abbott Laboratories
AbbVie
Abramsom Cancer Centre
Abraxis
Actavis
Allos Therapeutics
Amgen
Anthrogenesis
Arno Therapeutics
Array Biopharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
Biotest Pharmaceuticals
Bristol-Myers Squibb
Broad Institute
Cancer Research UK
Celanese
Celgene
Cell Genesys
Celldex Therapeutics
Cephalon
Constellation Pharmaceuticals
Cougar Biotechnology
Dana-Farber Cancer Institute
Dr. Reddy's Laboratories
Eli Lilly
Emcure Pharmaceuticals
Entremed
EntreMed
Epizyme
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Galapagos
Genentech
Genmab
Geron Corporation
GlaxoSmithKline (GSK)
Gliknik
Gloucester Pharmaceuticals
Harvard Medical School
Hospira
Human Genome Sciences
Immune System Therapeutics
ImmunoGen
Immunomedics
Janssen Biotech
Jerome Lipper Centre for Multiple Myeloma
Johnson & Johnson
Karyopharm Therapeutics
Kyowa Hakko Kirin Pharma
Kyowa Hakko Kirin Pharma
Leukosite
Lipomed
MD Anderson Cancer Centre
Merck & Co.
Millennium Pharmaceuticals
MorphoSys
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Mylan
Myogenics/ ProScript
Natco Pharma
National Institute for Health and Care Excellence (NICE)
Nereus Pharmaceuticals
Novartis
Oncolytics
OncoPep
Oncopeptides
Oncovir
Onyx Pharmaceuticals
Otsuka America Pharmaceutical
PDL BioPharma
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacyclics
PharmaMar
Pharmion
Pharmion
Roche
Rockefeller University
Seattle Genetics
Senesco Technologies
Signal Pharmaceuticals
Sun Pharma Global
Synta Pharmaceuticals
Takeda
Teva Pharmaceuticals
The World Health Organization (WHO)
Threshold Pharmaceuticals
Translational Genomics Research Institute
University of Arkansas
University of Illinois
US National Comprehensive Cancer Network
Watson Pharmaceuticals

Read the full report:
Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023
http://www.reportbuyer.com/pharma_healthcare/diseases/multiple_myeloma_treatments_world_drug_industry_market_2013_2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow